Today's Fresh Blogs...

• Analyst initiations 9-6-07: MSFT, CRM, TLEO and MFE

  Published: September 6, 2007, 7:13 am

  Tags: Analyst, Astrazeneca, Azn, Bfc Financial, Bfcfinancial, Bff, Capital Product Partners, Capitalproductpartners, Cplp, Crm, Firm, Glaxosmithkline, Gsk, Initiation, Lulu, Lululemon, Mcafee, Mfe, Microsoft, Msft, Novartis, Nvs, Rhhby, Roche Holding, Rocheholding, Salesforce Com, Sanof

  NVS) with a Buy rating and AstraZeneca (NYSE: AZN), Roche Holding (OTC: RHHBY), Sanofi-Aventis (NYSE: SNY) and GlaxoSmithKline (NYSE: GSK) with Neutral ratings. Deutsche Bank believes new product leverage can bring upside to consensus operating margin expectations at Microsoft Corporation (NASDAQ: MSFT) and they view shares as attractively

  Comments (0)   Blog link Rating: 0

• AstraZeneca's headaches worsened by new generic drug

  Published: November 5, 2007, 9:08 am

  Tags: Approval, Astrazeneca, Challenge, Cobalt, Drug, Generic, Money Amp Amp Stuff, Pharmaceutical, Version

  "The scale of the challenge posed to pharmaceutical companies by generic drug manufacturers was underlined yesterday when AstraZ read more

  Comments (0)   Blog link Rating: 0

• Analyst upgrades: AAPL, UBS, AZN and KLAC

  Published: April 7, 2008, 7:08 am

  Tags: Aapl, Aauk, Analyst, Anglo American, Angloamerican, Apple, Astrazeneca, Azn, Comscore, Inthenews, Kla Tencor, Klac, Scor, Ubs, Upgrade

  NOTEWORTHY: Apple, AstraZeneca and KLA-Tencor were today's noteworthy upgrades: Thomas Weisel upgraded Apple (NASDAQ: AAPL) to Overweight from Market Weight, citing a re-set in FY08 expectations and expected growth from Mac market share gains, accelerating iPhone revenue growth and increased iPhone ASPs. WestLB upgraded

  Comments (0)   Blog link Rating: 0

• Wyeth Pushing Pristiq Hard

  Published: April 22, 2008, 1:51 pm

  Tags: Medicine Medication, American Home Products, Antidepressant, Astrazeneca, Cnn Money, Cost, Desvenlafaxine, Discount, Drug, Drugs, Effexor, Effexor Xr, Eli Lilly, Fluoxetine, Heartburn Drug, Insurance, Insurance Companies, Medication, Meds, Patients, Pfizer, Prilosec, Pristiq

  drug, to compete with AstraZeneca's Prilosec. The drug generated $1.9 billion in profits for Wyeth last year. CNN Money reports that Teva Pharmaceuticals and Sun Pharmaceuticals began selling the generic version of the drug and handily cut into Wyeth's profits: the company reported a 4.6% decline in profit and a 66% drop in sales for the

  Comments (0)   Blog link Rating: 0

• Icahn Jabs Biogen Idec, Says Its Board Had `Very Little' Input in Sale Process

  Published: June 5, 2008, 12:57 pm

  Tags: Boston, Boston Blog Main, Biotech, Biogen Idec, Carl Icahn, James Mullen, Acquisitions, Stocks, Naomi Aoki, Medimmune, Astrazeneca

  billion sale of MedImmune to AstraZeneca. His efforts to repeat that history with Biogen haven’t worked out the same way, although if he gets his way on June 19, when shareholders will vote on his three nominees to the board, it could move him a step closer to another payday. Comments Permalink Share  E-mail

  Comments (0)   Blog link Rating: 0

• CEO Who Led Growth to Leave MedImmune

  Published: June 27, 2008, 12:00 am

  Tags: Ceo, Who, Led, Growth, Leave, Medimmune, Astrazeneca Group, Medimmune Inc, Synagis, John Holaday, Carl Icahn, Jamie Lacey, John T Mccamant, Tony Zook, Wayne T Hockmeyer, Maryland, David M Mott, Gaithersburg, Boston, David Brennan, H Thomas Watkins, Montgomery County Maryla

  MedImmune chief executive David M. Mott, who led the Gaithersburg biotech through years of rapid expansion and its sale to the British drug giant AstraZeneca, will leave the company at the end of July.

  Comments (0)   Blog link Rating: 0

• Boston Scientific Wins Stent Approval, Resolvyx Moves Closer to Fish-Oil Drug Trials, Codon Cuts Algae Fuel Deal, & More Life Sciences News

  Published: July 9, 2008, 12:28 am

  Tags: Boston, Boston Blog Main, Roundup, Life Sciences, Fda, Deals, Biotech, Boston Scientific, Astrazeneca, Cubist Pharmaceuticals, Fidelity Biosciences, Accuri Cytometers, Codon Devices, Algenol, Biofuels, Agios, Resolvyx, Third Rock Ventures, Flagship Ventures, Arch Venture

  $20 million a year to market AstraZeneca’s intravenous antibiotic Merrem. —CryoXtract, a startup launched by researchers from Harvard and Northeastern University, won the backing of Allied Minds, an investment firm focused squarely on very early technology from academic research labs. CryoXtract’s technology is a miniature

  Comments (0)   Blog link Rating: 0